Several clinical trials have explored CD19- and CD22-targeted CAR-T cells (NCT01044069 and NCT02315612), showing promising results in acute lymphoid leukemia (ALL), as well as CD19-targeted CAR-T cells in various non-Hodgkin lymphoma (NHL) subtypes (10–19). Here, CD19 is linked to non-Hodgkin lymphoma.